LabCorp to use more Illumina tech for diagnostic tool development; Danish team creates new pancreatic cancer test;

> As part of a new deal, LabCorp ($LH) will use a wider range of Illumina ($ILMN) next-generation gene sequencing products over the next several years to develop new diagnostic tools for a wide range of specialties. Item

> Danish scientists say they've developed a test for pancreatic cancer based on detecting microRNA molecules in whole blood. Story (reg. req.)

> Personal Genome Diagnostics in Baltimore will license technology from Johns Hopkins University that allows for improved detection of cancer mutations in circulating DNA. Item

> Researchers at the Karolinska Institutet in Sweden have found that using DNA tests for human papillomavirus allows for longer screening time between tests compared with old-fashioned cytology-based testing. Item

> A new blood test for celiac disease is designed to work in 24 hours, minus intestinal biopsies or requirements to eat gluten for a month or more. Story

Suggested Articles

Johnson & Johnson Vision announced that the worldwide president of its surgical business, Tom Frinzi, plans to retire at the end of this year.

Philips looked back on 15 years of data from one of its telehealth-equipped intensive care units, where centralizing operations reduced mortality.

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.